VBI VACCINES INC. (TSE:VBV) Files An 8-K Other Events

VBI VACCINES INC. (TSE:VBV) Files An 8-K Other Events
Item 8.01 Other Events.

On September 5, 2019, VBI Vaccines Inc. (the “Company”) issued a press release announcing that Jeff Baxter, president and chief executive officer of the Company, will present at the H.C. Wainwright 21st Annual Global Investment Conference. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated September 5, 2019


VBI Vaccines Inc/BC Exhibit
EX-99.1 2 ex99-1.htm     VBI Vaccines to Present at the H.C. Wainwright 21st Annual Global Investment Conference   CAMBRIDGE,…
To view the full exhibit click here

Story continues below

About VBI VACCINES INC. (TSE:VBV)

VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).

An ad to help with our costs